secwatch.observer — SEC 8-K summary
======================================

Issuer:     T2 Biosystems, Inc. (—)
CIK:        0001492674
Form:       8-K
Filed at:   2022-11-25T23:59:59+00:00
Accession:  0001193125-22-292611
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

T2 Biosystems receives Nasdaq delisting notice for MVLS below $35M minimum
--------------------------------------------------------------------------

- Received Nasdaq deficiency letter on Nov 22, 2022 for MVLS < $35M for 30 consecutive business days.
- Has 180 days, until May 22, 2023, to regain compliance under Nasdaq Listing Rule 5550(b)(2).
- Can regain compliance if MVLS closes at $35M+ for 10 consecutive business days.
- No immediate effect on listing or trading of common stock; delisting possible if not cured.
- Company may consider extension or appeal to Nasdaq Hearings Panel if non-compliance persists.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1492674/000119312522292611/0001193125-22-292611-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1492674/000119312522292611/d396110d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-292611

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer